|
Ketoconazole Plus Docetaxel to Treat Prostate Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Ketoconazole Plus Docetaxel to Treat Prostate Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Ketoconazole Plus Docetaxel to Treat Prostate Cancer Clinical research trials and Ketoconazole Plus Docetaxel to Treat Prostate Cancer healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Ketoconazole Plus Docetaxel to Treat Prostate Cancer. Ketoconazole Plus Docetaxel to Treat Prostate Cancer Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Ketoconazole Plus Docetaxel to Treat Prostate Cancer clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Ketoconazole Plus Docetaxel to Treat Prostate Cancer condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "K" Clinical Trials Conditions > Ketoconazole Plus Docetaxel to Treat Prostate Cancer  Ketoconazole Plus Docetaxel to Treat Prostate Cancer
Ketoconazole Plus Docetaxel to Treat Prostate Cancer
For Condition: Prostatic Neoplasms
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: High dose ketoconazole and weekly docetaxel have both been shown to have activity against androgen independent prostate cancer (AIPC). We have demonstrated synergy in prostate cancer in an in vitro model. This is an open label phase I study of high-dose ketoconazole plus weekly docetaxel in patients with metastatic AIPC. The primary objective of this study will be to determine the side effect profile of ketoconazole when combined with weekly docetaxel therapy and determine the maximum tolerated dose (MTD) and a recommended phase II dose (RPIID) of docetaxel when combined with high dose ketoconazole. Since ketoconazole may alter the metabolism of docetaxel, this study will evaluate potential drug interactions and adverse events between these two agents. Ketoconazole will be initiated at a dose of 400mg three times per day, plus 30mg of hydrocortisone (20mg in the morning and 10mg in the evening), plus docetaxel 5-43 mg/m(2) in a dose escalation (per section 3.2.2), repeated in 28-day cycles, comprising weekly treatments for three consecutive weeks followed by one week off. Each patient will be evaluated every four weeks for the duration of the study.
Details: High dose ketoconazole and weekly docetaxel have both been shown to have activity against androgen independent prostate cancer (AIPC). We have demonstrated synergy in prostate cancer in an in vitro model. This is an open label phase I study of high-dose ketoconazole plus weekly docetaxel in patients with metastatic AIPC. The primary objective of this study will be to determine the side effect profile of ketoconazole when combined with weekly docetaxel therapy and determine the maximum tolerated dose (MTD) and a recommended phase II dose (RPIID) of docetaxel when combined with high dose ketoconazole. Since ketoconazole may alter the metabolism of docetaxel, this study will evaluate potential drug interactions and adverse events between these two agents. Ketoconazole dose will be 800mg per day (given 200 mg in morning and afternoon, and 400 mg at night), plus 30mg of hydrocortisone (20mg in the morning and 10mg in the evening), plus docetaxel 5-43 mg/m(2) in a dose escalation (per section 3.2.2), repeated in 28-day cycles, comprising weekly treatments for three consecutive weeks followed by one week off. Each patient will be evaluated every four weeks for the duration of the study.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Male
Protocol Entry Criteria: INCLUSION CRITERIA: Patients must have histopathological documentation of prostate cancer confirmed in the Pathology Department of the Clinical Center at the National Institutes of Health or the National Naval Medical Center prior to starting this study. Patients whose pathology specimens are no longer available may be enrolled in the trial, if the patient has a clinical course consistent with prostate cancer and pathologic documentation of the diagnosis. Patients must have metastatic progressive androgen-independent prostate cancer (progressive prostate cancer while continuing to receive hormonal ablation, such as that of an LHRH agonist) documented prior to entry. Progression must be documented by at least one of the following parameters: 1. Two consecutively rising PSA levels, separated by at least one week, with at least one measurement that is 50% above the nadir reached after the last therapeutic maneuver (as long as the measurement is 5 ng/ml or greater); and/or, 2. At least one new metastatic deposit on Tc-99 bone scintigraphy; and/or, Progression of soft tissue metastases as measured by appropriate modalities (i.e., imaging, palpation): 1. Development of new area of malignant disease (measurable or non-measurable); 2. Measurable disease progression by RECIST criteria; 3. At least 4 weeks off of flutamide and 6 weeks off of bicultamide and nilutamide. Patients who have not undergone surgical castration must continue treatment with an LHRH agonist. If for some reason the LHRH agonist has been discontinued prior to entry on the study, then it should be reinstituted and disease progression must be documented. Patients must have a life expectancy of more than 3 months. Patients must have a performance status of 0 to 2 according to the ECOG criteria. Patients must have recovered from any acute toxicity related to prior therapy, including surgery. Hematological eligibility parameters (within 2 weeks before starting therapy): 1. Granulocyte count greater than or equal to 1,500/mm(3) 2. Platelet count greater than or equal to 100,000/mm(3) Biochemical eligibility parameters (within 2 weeks before starting therapy): 1. If the creatinine is greater than 1.5 mg/dl, a 24 hour urine collection must be obtained, and measured creatinine clearance must be at least 40 mL/min. 2. Hepatic function: Hepatic: Bilirubin less than 1.0 mg/dl, AST and ALT less than 2.5 times upper limit of normal. If the alkaline phosphatase is greater than 2.5 times the upper limit of normal, it must be fractionated and the hepatic alkaline phosphatase should be less than 2.5 times the upper limit of normal. Hormonal profile for patients with prostate cancer 1. All patients who have not undergone surgical castration must have a serum testosterone under 50 ng/ml and continue on their GnRh agonist. Patients must not have other active malignancies (within the past two years with the exception of non-melanoma skin cancers or carcinoma in situ of the bladder). Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment), New York Heart Assoc. class II-IV congestive heart failure are not eligible. Patients must be able to understand and sign an informed consent form. Patients must be willing to travel from their home to the NIH for follow-up visits. Patients must be greater than or equal to 18 years of age. Must be able to ingest oral medications to be eligible. EXCLUSION CRITERIA: Patients with brain metastases will not be eligible. Patients who have received strontium or samarium will not be eligible. HIV-positive patients receiving combination anti-retroviral therapy will be excluded because of possible pharmacokinetic interactions with ketoconazole, docetaxel or other agents administered during the study. In fact, ketoconazole has been found to increase the toxic effects of several protease inhibitors by affecting CYP3A4 activity. Patients on theophylline will be excluded. Patients who are receiving cisapride will be excluded. Patients who are receiving HMG-CoA inhibitors (lovastatin, atorvastatin, simvastatin, pravastatin and cerivastatin) Patients currently taking known inhibitors and/or inducers of CYP3A4; patients taking known substrates of CYP3A4 will be evaluated by the primary investigator. Patients who are receiving terfenadine, midazolam, triazolam, alprazolam, astemizole, loratadine, rifampin, isoniazid, dofetilide, pimozide, sirolimus or erythromycin will be excluded. Because gastric acidity is necessary for the dissolution and absorption of ketoconazole, concomitant administration of drugs which decrease gastric acid output or increase gastric pH (e.g., antacids, cimetidine, ranitidine, antimuscarinics, omeprazole, and lansoprazole) may decrease absorption and thus will be prohibited. Patients requiring warfarin will be excluded.
Total Enrollment: 36
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Katherine Fedenko 3014964026
Additional Information:
Study ID Numbers: 020149; 02-C-0149
Study Start Date: March 19, 2002
Record last reviewed: February 25, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00032825
Other Prostatic Neoplasms Studies:
1. YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
2. Safety and Efficacy of Atrasentan in Men with Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
3. Familial Prostate Cancer
4. A Phase III, Randomized Study of Atrasentan in Men with Non-Metastatic, Hormone-Refractory Prostate Cancer
5. Protein Measures of Outcome of Radiation Therapy for Prostate Cancer
Related Studies:
Other Prostatic Neoplasms Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Ketoconazole Plus Docetaxel to Treat Prostate Cancer
|
|
|
|
|
|
|
|
